Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1543-1548

  Chaturvedi, Vishnu ^a   Ramani, Rama ^a   Andes, David ^b   Diekema, Daniel J ^c   Pfaller, Michael A ^c   Ghannoum, Mahmoud A ^d   Knapp, Cindy ^e   Lockhart, Shawn R ^f   Ostrosky Zeichner, Luis ^g   Walsh, Thomas J ^h   Marchillo, Karen ^b   Messer, Shawn ^d   Welshenbaugh, Amanda R ^d   Bastulli, Cara ^e   Iqbal, Noreen ^f   Paetznick, Victor L ^g   Rodriguez, Jose ^g   Sein, Tin ^h  

^a WADSWORTH CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e Trek Diagnostic Systems   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN; POSACONAZOLE; PYRROLE; VORICONAZOLE;

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; DISPERSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGAL STRAIN; FUNGUS GROWTH; FUNGUS ISOLATION; IC 50; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SCORING SYSTEM; SPECTROPHOTOMETER;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA GLABRATA; DRUG COMBINATIONS; ECHINOCANDINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; INHIBITORY CONCENTRATION 50; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 79953226274     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01510-09     Document Type: Article

References (50)

1. Almyroudis, N. G., and B. H. Segal. 2009. Prevention and treatment of invasive fungal diseases in neutropenic patients. Curr. Opin. Infect. Dis. 22:385-393.
2. Andes, D. 2003. Clinical pharmacodynamics of antifungals. Infect. Dis. Clin. North Am. 17:635-649.
3. Anonymous. 1992. Synergism testing: broth microdilution checkerboard and broth macrodilution methods, p. 5.18.1-5.18.28. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, DC.
4. Antachopoulos, C., et al. 2005. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole. J. Pediatr. Hematol. Oncol. 27:283-285.
5. Antachopoulos, C., and T. J. Walsh. 2005. New agents for invasive mycoses in children. Curr. Opin. Pediatr. 17:78-87.
6. Arikan, S. 2007. Current status of antifungal susceptibility testing methods. Med. Mycol. 45:569-587.
7. Baddley, J. W., and P. G. Pappas. 2005. Antifungal combination therapy: clinical potential. Drugs 65:1461-1480.
8. Barchiesi, F., et al. 2004. In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob. Agents Chemother. 48:3317-3322.
9. Barchiesi, F., E. Spreghini, S. Tomassetti, D. Giannini, and G. Scalise. 2007. Caspofungin in combination with amphotericin B against Candida parapsilosis. Antimicrob. Agents Chemother. 51:941-945.
10. Canton, E., A. Espinel-Ingroff, and J. Peman. 2009. Trends in antifungal susceptibility testing using CLSI reference and commercial methods. Expert Rev. Anti Infect. Ther. 7:107-119.
11. Canton, E., J. Peman, M. Gobernado, A. Viudes, and A. Espinel-Ingroff. 2005. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob. Agents Chemother. 49:1593-1596.
12. Chaturvedi, V., et al. 2008. Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei. Antimicrob. Agents Chemother. 52:1500-1502.
13. CLSI. 2007. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
14. CLSI. 2007. Reference method for broth dilution antifungal susceptibility testing of yeasts. Informational supplement. M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Cuenca-Estrella, M. 2004. Combinations of antifungal agents in therapy - what value are they? J. Antimicrob. Chemother. 54:854-869.
16. Cuenca-Estrella, M., et al. 2007. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 13:1018-1022.
17. Dumaine, V., et al. 2008. Successful treatment of prosthetic knee Candida glabrata infection with caspofungin combined with flucytosine. Int. J. Antimicrob. Agents 31:398-399.
18. Falcone, M., et al. 2009. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) 88:160-168.
19. Fohrer, C., et al. 2006. Antifungal combination treatment: a future perspective. Int. J. Antimicrob. Agents 27:25-30.
20. Forrest, G. 2006. Role of antifungal susceptibility testing in patient management. Curr. Opin. Infect. Dis. 19:538-543.
21. Girmenia, C., M. Venditti, and P. Martino. 2003. Fluconazole in combination with flucytosine in the treatment of fluconazole-resistant Candida infections. Diagn. Microbiol. Infect. Dis. 46:227-231.
22. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
23. Groll, A. H., and H. Kolve. 2004. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur. J. Clin. Microbiol. Infect. Dis. 23:256-270.
24. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
25. Klepser, M. E., E. J. Ernst, R. E. Lewis, M. E. Ernst, and M. A. Pfaller. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212.
26. Kontny, U., T. J. Walsh, J. Rossler, M. Uhl, and C. M. Niemeyer. 2007. Successful treatment of refractory chronic disseminated candidiasis after prolonged administration of caspofungin in a child with acute myeloid leukemia. Pediatr. Blood Cancer 49:360-362.
27. Kontoyiannis, D. P., and R. E. Lewis. 2003. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist. Updat. 6:257-269.
28. Kontoyiannis, D. P., and R. E. Lewis. 2004. Toward more effective antifungal therapy: the prospects of combination therapy. Br. J. Haematol. 126:165-175.
29. Lewis, R. E., D. J. Diekema, S. A. Messer, M. A. Pfaller, and M. E. Klepser. 2002. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J. Antimicrob. Chemother. 49:345-351.
30. Lopez-Ciudad, V., et al. 2006. Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect. Dis. 6:73.
31. Mackay, M. L., K. Milne, and I. M. Gould. 2000. Comparison of methods for assessing synergic antibiotic interactions. Int. J. Antimicrob. Agents 15:125-129.
32. Meletiadis, J., P. E. Verweij, D. T. TeDorsthorst, J. F. Meis, and J. W. Mouton. 2005. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med. Mycol. 43:133-152.
33. Mukherjee, P. K., D. J. Sheehan, C. A. Hitchcock, and M. A. Ghannoum. 2005. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev. 18:163-194.
34. Nishi, I., A. Sunada, M. Toyokawa, S. Asari, and Y. Iwatani. 2009. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species. J. Infect. Chemother. 15:1-5.
35. Nivoix, Y., et al. 2006. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J. Infect. 52:67-74. (Pubitemid 43115510)
36. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
37. Ostrosky-Zeichner, L., et al. 2005. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis. 24:654-661.
38. Perea, S., G. Gonzalez, A. W. Fothergill, D. A. Sutton, and M. G. Rinaldi. 2002. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J. Clin. Microbiol. 40:1831-1833.
39. Pfaller, M. A., et al. 2009. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 47:117-123.
40. Pfaller, M. A., et al. 2008. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46:842-849. (Pubitemid 351379967)
41. Pfaller, M. A., et al. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
42. Pfaller, M. A., et al. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
43. Rex, J. H., et al. 2003. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36:1221-1228.
44. Roling, E. E., et al. 2002. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus [sic] neoformans via time-kill methods. Diagn. Microbiol. Infect. Dis. 43:13-17.
45. Saiman, L., Y. Chen, P. S. Gabriel, and C. Knirsch. 2002. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 46:1105-1107.
46. Schilling, A., M. Seibold, V. Mansmann, and B. Gleissner. 2008. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/ posaconazole therapy. Med. Mycol. 46:79-83.
47. Soares, B. M., et al. 2008. Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing. Rev. Iberoam. Micol. 25: 242-245.
48. Sobel, J. D. 2004. Combination therapy for invasive mycoses: evaluation of past clinical trial designs. Clin. Infect. Dis. 39:S224-S227.
49. Te Dorsthorst, D. T. A., et al. 2002. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob. Agents Chemother. 46:2982-2989.
50. Vehreschild, J. J., et al. 2006. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation. Mycoses 49(Suppl. 1):42-47. (Pubitemid 44370102)